Sonia Giknavorian, MD
Geriatric Medicine · Phoenix, AZNPI 1225132608
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 26.6% of the total. Reporting peaked in 2024 at $252 and has fallen 84.8% since, to $38 in 2025.
Across 55 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$251
- Lilly USA, LLC$133
- Pfizer$116
- Xeris Pharmaceuticals, Inc.$60
- Boston Scientific$56
- Amarin Pharma, Inc.$45
- plus $284 from 15 others
What the payments were for
- Food & beverage$945100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $251 |
| Lilly USA, LLC | 8 | $133 |
| Pfizer | 8 | $116 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Boston Scientific | 2 | $56 |
| Amarin Pharma, Inc. | 3 | $45 |
| Merck | 2 | $32 |
| GSK | 2 | $29 |
| Johnson & Johnson | 2 | $24 |
| Exact Sciences | 1 | $23 |
| Abbott | 1 | $23 |
| Novartis | 1 | $18 |
| AbbVie | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
How this compares
$945 in reported general payments places this provider in the 75th percentile of 75 geriatric medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 121 | $165,266 |
| EliquisApixaban | 65 | $91,072 |
| TrulicityDulaglutide | 50 | $69,576 |
| OzempicSemaglutide | 46 | $64,986 |
| MounjaroTirzepatide | 34 | $52,329 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $51,332 |
| JanuviaSitagliptin Phosphate | 16 | $21,813 |
| XareltoRivaroxaban | 14 | $18,258 |
| LinzessLinaclotide | 15 | $15,779 |
| Spiriva RespimatTiotropium Bromide | 14 | $14,035 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $12,260 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $9,822 |
| Ezetimibe | 406 | $8,069 |
| Novolog FlexpenInsulin Aspart | 22 | $6,678 |
| LantusInsulin Glargine,hum.Rec.Anlog | 20 | $5,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $133 | $121,90584 claims |
| PfizerEliquis | $116 | $91,07265 claims |
| Novo NordiskOzempic | $15 | $64,98646 claims |
| GSKTrelegy Ellipta | $29 | $51,33238 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $251 | $22,08334 claims |
| MerckJanuvia | $32 | $21,81316 claims |
| Johnson & JohnsonXarelto | $24 | $18,25814 claims |
| AbbVieLinzess | $18 | $15,77915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 75 geriatric medicine providers in Arizona.
Other geriatric medicine in Phoenix
- Robin MacdougallPhoenix$51K
- Anil NandaPhoenix$4K
- Kehart Flom RacomaPhoenix$374
- Rex RagsdalePhoenix$232
- Walter NieriPhoenix$161
- Suzanne CombsPhoenix$127
- Serene MusallamPhoenix$126
- Aimee BaekPhoenix$102
- Maria BellantoniPhoenix$77
- Gary SalzmanPhoenix$63
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.